D&D Pharmatech 2launch of a phase trial · Hyundai Engineering 3participation in a trillion-won project and more 7month 8day key disclosures

D&D Pharmatech's global technology-transfer partner 2026year 7month 8day began a clinical 2trial of a candidate FAP-targeted contrast agent. The start of a clinical trial is a key step for assessing commercialization potential.

SD Biosensor 2026year 7month 8day said it would target the global public procurement market with tuberculosis diagnostic products. The company plans to expand the countries targeted for public procurement and preparations for bidding.

Cheongdam Global 2026year 7month 8day announced that it would expand the brands participating in global pop-up and trade fair projects. The plan is to increase overseas exhibition and event participation by adding brand partners.

Digital Daesung 2026 year 7 month 7 day announced that it had strengthened the growth foundation of its reading education brand, Hanuri. The company explained that it would secure growth momentum through organizational and service advancements.

Hyundai Engineering said on 2026 year 7 month 8 day that it would participate in a joint Korea-U.S. lithium and boron plant project. The report specified the project scale as approximately '3 trillion won'.

These announcements were concentrated from 2026 year 7 month 7 to 8 day. They concerned different matters: the launch of a clinical trial, overseas public procurement, the expansion of global events, the strengthening of an education brand, and participation in a large-scale plant project.